Pregnancy Clinical Trial
Official title:
RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil
The perinatal morbidity and mortality rates for Brazil are five to ten-fold higher than those reported for upper income countries. This study tests the likelihood that the joint administration of antioxidants vitamin C (1000 mg) and vitamin E (400 IU) will reduce the incidence of preeclampsia among chronically hypertensive pregnant patients and patients with a past history of preeclampsia/eclampsia.
The maternal, perinatal and neonatal morbidity and mortality rates for Brazil are five to
ten-fold higher than those reported for upper income countries. In Sao Paulo, 22 percent of
maternal deaths are attributable to hypertensive complications of pregnancy, which ranks as
the number one cause of maternal death. Recent advances in the understanding of the
pathophysiology of preeclampsia suggest the possibility of antioxidant therapy for the
prevention of preeclampsia. The primary hypothesis is that the joint administration of the
antioxidants vitamin C (1000 mg) and vitamin E (400 IU) will reduce the incidence of
preeclampsia among chronically hypertensive pregnant patients and patients with a past
history of preeclampsia/eclampsia. Secondary outcomes include severity of preeclampsia;
incidence of gestational hypertension; incidence of premature rupture of the membranes;
incidence of preterm birth; incidence of low birth weight infants; biomarker level
correlation with preeclampsia.
Study sites are high-risk obstetrical clinics in the Brazilian cities of Recife, Botucatu,
Campinas, and Porto Alegre. The sample size was based on an estimated risk of
preeclampsia/eclampsia of 21-25% in the control group. The study hypothesizes a 40% absolute
reduction of risk of preeclampsia; early treatment withdrawal of 3%; withdrawal of consent
or loss to follow-up of 10%; calculated at a 0.05 significance level with 80% power. Seven
hundred thirty-four obstetric patients with chronic hypertension or preeclampsia in the
prior pregnancy presenting for care between 12 weeks and 19 weeks', 6 days gestation will be
randomized to a double-blinded placebo controlled trial to receive a daily dose of either
vitamin E (400 International Units) and vitamin C (1000 mg) or placebo from the time of
enrollment to delivery. The use of MEMS caps enables researchers to accurately track
compliance.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT02408315 -
Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)
|
Phase 3 |